Scancell Holdings (LSE:SCLP) has released updated findings from its SCOPE Phase 2 trial, showing that its iSCIB1+ immunotherapy—used alongside standard checkpoint inhibitors—offers a meaningful improvement in progression-free survival (PFS) for patients with advanced melanoma. The therapy achieved a 74% PFS rate at 16 months, well above the current standard of care, which delivers around 50% PFS at 11.5 months. Early overall survival data also point to a 14% uplift. These promising results have informed ongoing regulatory discussions, with agencies aligned on key design features and endpoints for potential late-stage studies. The data strengthen Scancell’s position within the cancer immunotherapy space and suggest the therapy could ultimately reshape treatment paradigms for melanoma.
Scancell’s broader outlook continues to be weighed down by its weak financial footing, including negligible revenue and substantial losses. Nonetheless, the company’s clinical progress and pipeline momentum provide important offsets, signalling upside potential if late-stage trials replicate current success. Technical indicators reflect mixed sentiment—near-term bullishness tempered by overbought conditions—while valuation remains stretched given existing financial constraints. Overall, the science is advancing, but financial risks keep the outlook cautious.
More about Scancell Holdings
Scancell Holdings plc is a clinical-stage biotech focused on developing off-the-shelf active immunotherapies designed to elicit durable, tumour-specific immune responses. Its lead candidate, iSCIB1+, is an enhanced DNA vaccine within the company’s ImmunoBody® platform and is currently in Phase 2 testing for melanoma. Scancell is also advancing Modi-1, a peptide-based therapy from its Moditope® platform, and has established GlyMab Therapeutics Ltd. to develop high-affinity antibodies that target tumour-specific glycans.
Leave a Reply